In a propensity-matched real-world cohort of 32,448 adults with chronic kidney disease, adding a GLP-1 receptor agonist to existing SGLT2 inhibitor therapy — versus SGLT2i alone — reduced major adverse kidney events by 30% (HR 0.70), major cardiovascular events by 17% (HR 0.83), and all-cause mortality by a striking 45% (HR 0.55) over a median 12-month follow-up. Benefits were consistent across CKD stages and regardless of diabetes status, but were most pronounced in patients with obesity, heart failure, or ischemic heart disease.
These findings matter because CKD affects roughly 850 million people globally and carries catastrophic cardiorenal risk. Both drug classes independently earned landmark trial support — SGLT2i through CREDENCE and DAPA-CKD, GLP-1 agonists through FLOW — but head-to-head combination data have been conspicuously absent. This analysis, drawing on over 112,000 patients, is the largest real-world signal yet suggesting synergistic rather than merely additive benefit. The 45% mortality reduction is especially striking, though observational design limits causal inference: residual confounding, short follow-up (12 months), and channeling bias toward healthier combination-therapy candidates cannot be ruled out. The gastrointestinal side effects and retinopathy progression signal warrant monitoring. Still, the consistency across subgroups and the sheer cohort size elevate this beyond incremental noise — it provides strong equipoise justification for a dedicated randomized trial, which renal and cardiovascular medicine urgently needs.